NCT04919135 - Mesenchymal Stem/Stromal Cell Therapy in the Treatment of Frailty | Biotech Hunter

Enrollment

158

Participants

Timeline

Start Date

October 19, 2021

Primary Completion Date

April 20, 2023

Study Completion Date

December 30, 2024

Conditions

Frailty

Interventions

BIOLOGICAL

Umbilical Cord Mesenchymal Stem Cells transplantation

Patients assigned to UC-MSC administration groups will receive two administrations at a dose of 1.5 million cells/kg patient body weight via the IV route with a 3-month intervening interval

DRUG

standard frailty treatment and supplementary medication

Hightamine (Hankook Korus Pharm, Korea), Total calcium (Nugale Pharmaceutical, Canada), Bioflex (Ausbiomed, Australia)

Trial Locations (1)

100000

Vinmec Research Institute of Stem Cell and Gene Technology, Hanoi

All Listed Sponsors

lead

Vinmec Research Institute of Stem Cell and Gene Technology

OTHER